Cancer chemotherapy should aim to benefit patients by improving either the duration of survival or the quality of that survival. Patient survival is measured easily, but valid methods for the assessment of physical, social and emotional health have been more difficult to develop. The definition of quality of life (QL) is essentially a philosophical problem and there are no "gold standards" to which QL assessments can be compared. However the development of reliable measures of QL is important since the aim of most trials of chemotherapy is palliation, and the assumption that tumour shrinkage correlates with overall benefit to patients may not always be justified.
A number of methods for assessing QL have been reported, including the QL Index (Spitzer et al., 1981) : The Sickness Impact Profile (Berger et al., 1981a, b) ; and linear analogue self-assessment (LASA) (Priestman & Baum, 1976) . A QL instrument based upon LASA technique has been developed at this institute and is the subject of a previous report (Selby et al., 1984) . This instrument appears to be a valid measure of QL parameters, gives reproducible results and is manageable in the clinical setting.
In the present study we have applied the QL instrument to two groups of patients taking part in a randomized trial of the use of either high dose or low dose chemotherapy for metastatic breast cancer. We have used the instrument to address three questions:
(i) Does the instrument allow discrimination between two groups of patients with similar disease parameters but whose treatment would be expected to elicit quite different levels of toxicity?
( Study design The QL instrument has been described in detail previously (Selby et al., 1984 Patients were assessed on two occasions (Table  II) . In this study the independent observer was a physician (D.B.) who was not involved in the clinical management of these patients. The first asessment occurred in the clinic 3 weeks after a course of chemotherapy, just before the (5.3-9.9) (3.0-9.9) (6.6-9.9) (0-9.4) (0.6-9.9) (3.0-9.9) (2.3-9.6) (2.6-9.9) Vomiting 9.68 9.66 9.67 9.61 9.68 9.68 7.95 8.12
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(9.1-9.9) (9.5-9.9) (5.7-9.9) (5.4-9.9) (9.5-9.9) (9.7-9.9) (5.2-9.9) (7.4-9.9) difference between the two groups for vomiting (P = 0.002) -and alopecia (P= 0.04), while the difference for diarrhoea approached significance (P = 0.08). When physician scores from this second assessment were compared, statistically significant differences were found for nausea (P = 0.04), vomiting (P= 0.01) and diarrhoea (P= 0.05). At this second assessment discrimination between the high and low dose CMF groups could be made on four of the six toxicity dimensions. Table IV shows Spearman's rank correlation coefficients for patient and physician scores of toxicity dimensions. Good agreement is seen for most dimensions (r, > 0.5). The correlation coefficient was <0.5 for dysuria: however, patient and physician scores were high (mean>9.0) with small variance, so that substantial agreement is not evident because of poor dispersal of data. There was also good agreement for the general health and disease related dimensions (data not shown). Only for appearance, relationships, hobbies, anxiety, concentration, anger, breathing and sleep were correlation coefficients less than 0.5. Once again substantial agreement was masked by poor dispersal of the data for concentration and breathing.
In general there appears to be good agreement between self-rating and independent observer assessment of the same QL dimension. Differences in toxicity between high and low dose CMF regimens are to be expected. Our results demonstrate that this QL instrument can discriminate between different levels of treatment related toxicity, even among a small patient sample. We found differences between the patient groups in the first assessment made 3 weeks after chemotherapy for the dimensions of alopecia and diarrhoea; differences in the second assessment at 24 h after chemotherapy were present for the dimensions of nausea, vomiting, alopecia, and diarrhoea. It seems likely that patient recall has underestimated toxicity experienced 3 weeks previously. The toxicities of alopecia and diarrhoea may be more lingering and thus more easily recalled than the more acute and short-lived toxicities of nausea and vomiting. There appears to be better recall of acute toxicity when QL assessment is made closer to the time chemotherapy administration.
Currently the evaluation of this QL instrument shows that there are minor differences in discriminative capacity when the instrument is used for self-rating compared with its use by an independent observer. Although the good correlation between patient and physician scores indicate that they were both assessing similar aspects of QL, the minor discriminative differences suggests that the most valuable QL information may come from combining self-rating with assessment by an independent observer. Currently a larger study is underway at this institution: its aims are to determine whether or not differences may exist in other dimensions between groups of patients with breast cancer, to assess change in LASA with time, and to correlate change in LASA with response to chemotherspy.
Quality of life assessment should become an integral part of all clinical trials that seek to assess the impact of treatment on palliation. The present instrument has potential for routine clinical use. It can be used readily by patients themselves as well as by independent observers, and we have shown evidence of its discriminative capacity in this small group of patients. Information on QL is critical in the determination of the overall effectiveness of chemotherapy regimens and in the comparison of different regimens.
